Compare NHP & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NHP | EVO |
|---|---|---|
| Founded | N/A | 1993 |
| Country | United States | Germany |
| Employees | N/A | 4553 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 778.3M |
| IPO Year | 2012 | 2007 |
| Metric | NHP | EVO |
|---|---|---|
| Price | $16.41 | $1.96 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | ★ 543.9K | 47.3K |
| Earning Date | N/A | 04-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 65.09 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $342,279,000.00 | N/A |
| Revenue This Year | N/A | $1.37 |
| Revenue Next Year | N/A | $10.05 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $13.68 | $1.90 |
| 52 Week High | $17.46 | $4.27 |
| Indicator | NHP | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 59.65 | 38.88 |
| Support Level | $14.54 | $1.90 |
| Resistance Level | $17.17 | $3.84 |
| Average True Range (ATR) | 0.79 | 0.05 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 60.99 | 21.31 |
National Healthcare Properties Inc is a publicly registered real estate investment trust. It is focused on acquiring, owning, and managing a diversified portfolio of healthcare real estate assets focused on senior housing operating properties (SHOP) and outpatient medical facilities (OMF) in the United States. The company operates in two reportable business segments: SHOP and OMF. The SHOP segment consists of assisted living communities, memory care communities and independent living communities, which are focused on needs-based assisted living and memory care. The OMF segment consists of physicians' offices and examination rooms, hospitals, pharmacies, hospital ancillary service space and other outpatient services. The majority of revenue is derived from the SHOP segment.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.